Researchers from the Netherlands argue that variants in ANK1 and SPTB may lead to heightened severity of HS manifestations in contrast to SPTA1, with these patients typically having lower hemoglobin and higher reticulocyte levels. Here, ANK1 is linked to histiocytic sarcoma.